BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancerGoldie Y.L. Lui, Carla Grandori, Robert L. Diaz et al.|EBioMedicine|2020Cited by 38
Abstract 1619: Personalized medicine: A CLIA-certified high-throughput drug screening platform for ovarian cancerHallie A. Swan, Carla Grandori, Rachele Rosati et al.|Cancer Research|2018Cited by 5
Abstract GMM-051: A CLIA-CERTIFIED HIGH-THROUGHPUT DRUG SCREENING PLATFORM FOR OVARIAN CANCER TO INFORM PERSONALIZED CANCER CARE AND DISCOVER NOVEL COMBINATIONSFranz X. Schaub, Carla Grandori, VK Gadi et al.|Clinical Cancer Research|2019Cited by 0